Apotex Is Appealing Plavix Patent Ruling, Links Case to Norvasc
Executive Summary
Apotex contends that Plavix is an obvious invention in the same way Norvasc is, but a district court judge made a sharp distinction between the two drugs in ruling that Apotex had failed to prove the patent covering Plavix is invalid or unenforceable
You may also be interested in...
Generic Plavix Is Expected to Launch in Germany In Mid-August
The two companies with rights to market a generic version of Plavix (clopidogrel) in Germany are mum about their launch date. But Sanofi-Aventis, which markets Plavix with Bristol-Myers Squibb, does not expect to see generic products on the German market before mid-August
Generic Plavix Is Expected to Launch in Germany In Mid-August
The two companies with rights to market a generic version of Plavix (clopidogrel) in Germany are mum about their launch date. But Sanofi-Aventis, which markets Plavix with Bristol-Myers Squibb, does not expect to see generic products on the German market before mid-August
Bristol Readies For Prasugrel’s Impact On Plavix, Files DPP-4 Inhibitor
Despite downplaying any concern, Bristol-Myers Squibb is preparing for a potential challenge to its blockbuster anti-clotting drug Plavix from Lilly/Daiichi Sankyo's Effient (prasugrel)